MOTS-c is a mitochondrial-derived peptide studied mainly for metabolic regulation, exercise physiology, insulin sensitivity, and cellular stress responses. Its evidence grade is A because at least two human randomized controlled trials are indexed in PubMed, but that grade reflects study quantity and design—not proof that MOTS-c works or is safe for patient use.
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →What it is
MOTS-c is a small mitochondrial-derived peptide, also called MOTSc or mitochondrial ORF of the 12S rRNA type-c. It is described in reviews as a mitokine, meaning a mitochondria-linked signal that may help cells communicate during exercise and metabolic stress 7, 8.
In plain English: mitochondria are not just “power plants.” They also make signals. MOTS-c is one of those signals, and researchers are studying whether changes in MOTS-c relate to glucose metabolism, insulin resistance, exercise adaptation, and other stress responses 7, 8.
This page is education-only. MOTS-c is not FDA-approved, and Chia does not currently offer MOTS-c. If you are comparing it with other mitochondrial peptides or reading about online access, the safety question is not just “where can I buy it?” It is whether any peptide is being evaluated by a licensed clinician and dispensed through an appropriate pharmacy process.
| Name readers may see | What it means | Evidence context |
|---|---|---|
| MOTS-c | Mitochondrial-derived peptide | Studied in human exercise and biomarker studies 2, 4 |
| MOTSc | Alternate spelling without the hyphen | Usually refers to the same peptide discussed in MOTS-c papers 7 |
| Mitochondrial ORF of the 12S rRNA type-c | Expanded scientific name | Used in review literature on exercise and mitohormesis 7 |
| Mitokine | A mitochondria-linked signaling molecule | Studied as part of cellular stress and metabolic signaling 5, 7 |
Mechanism of action
MOTS-c is proposed to work as a mitochondria-to-nucleus signal during metabolic stress. In mechanistic research, MOTS-c was reported to move into the nucleus and regulate nuclear gene expression in response to metabolic stress; that supports a proposed pathway, not a proven patient outcome 12.
Mitochondrial-derived peptide signaling
Mitochondrial-derived peptides are short peptides encoded in mitochondrial DNA. Reviews describe MOTS-c and related peptides as signals that may help coordinate metabolism, exercise response, and stress adaptation 7, 8.
Human studies have measured circulating MOTS-c after acute endurance exercise and after exercise programs in breast cancer survivors. These studies support MOTS-c as a measurable physiology marker, but they do not show that taking MOTS-c improves performance or health outcomes 2, 4.
Metabolic stress, nuclear signaling, and AMPK-related pathways
The 2018 Cell Metabolism study reported that MOTS-c can translocate to the nucleus and affect nuclear gene expression under metabolic stress conditions. That kind of mechanistic work helps explain why researchers are interested in AMPK-related metabolic signaling, but it does not establish a clinical use by itself 12.
Animal research also reported effects on metabolic homeostasis, obesity, and insulin resistance in experimental models. Because that finding was in animal and experimental systems, it should not be read as proof that MOTS-c causes weight loss or improves insulin resistance in people 9.
Evidence
MOTS-c receives an evidence grade of A under the supplied rubric because at least two human randomized controlled trials are indexed in PubMed. That grade describes the amount and design of the published evidence, not whether MOTS-c works, not whether it is safe, and not whether it should be used by a patient.
What an A grade does and does not mean
The retrieved PubMed list includes randomized controlled trials involving circulating MOTS-c levels in humans, including studies in acute endurance exercise, exercise interventions in breast cancer survivors, patients with breast cancer treated with metformin, and repeated heat stress during calf muscle immobilization 1, 2, 4, 5.
That is helpful, but it is not the same as a set of large trials showing that MOTS-c improves symptoms, body weight, glucose control, cancer outcomes, or lifespan. Several human studies measure MOTS-c as a biomarker or mitokine; biomarker movement can be important science without proving a treatment effect 1, 3, 5.
| Evidence type | What the retrieved evidence includes | What it can support | What it cannot prove |
|---|---|---|---|
| Human randomized studies | Exercise, metformin-related, and heat-stress studies measuring circulating MOTS-c 1, 2, 4, 5 | MOTS-c is measurable in human physiology research | That MOTS-c is an effective treatment |
| Human clinical research | A type 2 diabetes and coronary artery disease study examining MOTS-c with platelet reactivity and outcomes 3 | MOTS-c may be studied as a biomarker in complex cardiometabolic disease | That MOTS-c improves cardiovascular outcomes |
| Animal research | Animal data reporting metabolic homeostasis, obesity, and insulin resistance findings 9 | A reason to study human metabolic questions | Human weight-loss or diabetes benefit |
| Cell and mechanistic research | Nuclear gene expression response under metabolic stress 12 | A proposed mechanism | Clinical safety or benefit |
| Reviews | Summaries of MOTS-c, exercise, mitohormesis, and therapeutic interest 7, 8 | Context and hypothesis-building | Definitive efficacy |
What benefits has MOTS-c been studied for?
MOTS-c has been studied for exercise physiology, insulin sensitivity, glucose metabolism, obesity-related biology, cancer-related biomarkers, and cardiometabolic risk markers. The careful wording matters: these are studied areas, not established benefits for patient use 1, 2, 3, 4, 9.
For a plain-language overview of claimed benefits versus what the evidence can actually support, see our guide to MOTS-c peptide benefits.
Exercise physiology and circulating MOTS-c levels
A human randomized controlled study reported that acute endurance exercise stimulated circulating levels of mitochondrial-derived peptides in humans. This supports MOTS-c as part of exercise physiology research, not as proof that MOTS-c is a performance treatment 2.
Another randomized study looked at aerobic and resistance exercise effects on MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. The endpoint was the mitochondrial peptide MOTS-c in the setting of exercise, not a claim that MOTS-c itself improves cancer survivorship outcomes 4.
Insulin sensitivity, glucose metabolism, and obesity-related research
Preclinical animal research reported that MOTS-c promoted metabolic homeostasis and reduced obesity and insulin resistance in experimental models. Because this was animal evidence, it cannot be converted into a claim that MOTS-c causes weight loss, burns belly fat, or improves diabetes in humans 9.
A registered Phase 2 trial is recruiting adults with prediabetes and overweight or obesity to study MOTS-c for improving insulin sensitivity. A registered trial is a sign that the question is being tested; it is not completed evidence of benefit 13.
Cancer-related observational and clinical research signals
A randomized controlled trial studied circulating MOTS-c levels in patients with breast cancer treated with metformin. This supports discussion of MOTS-c as a measured biomarker in a cancer-related setting, not as evidence that MOTS-c is a cancer treatment 1.
A separate primary study reported MOTS-c-related findings in ovarian cancer progression through a USP7-mediated LARS1 deubiquitination pathway. That type of work is early and mechanistic; it should not be used to make patient treatment claims 10.
What studies exist
| Year | Design | Study | Journal | Record |
|---|---|---|---|---|
| 2022 | Randomised controlled trial | Circulating levels of MOTS-c in patients with breast cancer treated with metformin | Aging | PMID 36490309 |
| 2021 | Randomised controlled trial | Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans | Journal of applied physiology (Bethesda, Md. : 1985) | PMID 34351816 |
| 2025 | Randomised controlled trial | Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization | Medicine and science in sports and exercise | PMID 40674654 |
| 2020 | Clinical trial | β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary a | Journal of thrombosis and thrombolysis | PMID 32052315 |
| 2021 | Randomised controlled trial | Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors | Scientific reports | PMID 34413391 |
| 2022 | Review / secondary | Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c) | Diabetes & metabolism journal | PMID 35656563 |
| 2023 | Review / secondary | MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation | Frontiers in endocrinology | PMID 36761202 |
| 2015 | Primary study | The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance | Cell metabolism | PMID 25738459 |
| 2024 | Primary study | Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination | Advanced science (Weinheim, Baden-Wurttemberg, Germany) | PMID 39321430 |
| 2022 | Primary study | The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus | Pharmacological research | PMID 34798268 |
| 2018 | Primary study | The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress | Cell metabolism | PMID 29983246 |
| 2026 | Review / secondary | Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance | Sports medicine (Auckland, N.Z.) | PMID 41966639 |
| Registration | Phase | Status | Enrolment | Title |
|---|---|---|---|---|
| NCT07505745 | PHASE2 | RECRUITING | 120 | MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity |
| NCT07678073 | NA | RECRUITING | 68 | Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation |
| NCT04027712 | N/A | UNKNOWN | 120 | Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD |
| NCT03878706 | N/A | RECRUITING | 240 | The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination |
| NCT06133946 | N/A | ACTIVE_NOT_RECRUITING | 35920 | Cohort Of DEafness-gene Screening |
This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-07.
Reported dosing ranges
No human dosing has been published. In the retrieved human evidence, MOTS-c is mainly measured as a circulating peptide or biomarker; the records do not establish a patient dosing range for MOTS-c administration 1, 2, 4, 5.
| Source category | What was studied or recorded | Reported MOTS-c dosing range | How to interpret it |
|---|---|---|---|
| Human randomized trial: acute endurance exercise | Circulating mitochondrial-derived peptides after exercise 2 | No administered MOTS-c dosing range reported | Supports biomarker discussion, not dosing guidance |
| Human randomized trial: exercise in breast cancer survivors | Effect of aerobic and resistance exercise on MOTS-c 4 | No administered MOTS-c dosing range reported | Supports exercise physiology research context |
| Human randomized trial: breast cancer and metformin | Circulating MOTS-c in patients treated with metformin 1 | No administered MOTS-c dosing range reported | Supports biomarker research context |
| Human randomized trial: heat stress and immobilization | MOTS-c and FGF21 levels during repeated heat stress and calf muscle immobilization 5 | No administered MOTS-c dosing range reported | Supports mitokine measurement in physiology research |
| Registered Phase 2 trial | MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight or obesity 13 | No completed published dosing result available in the retrieved record | Trial registration is not dosing evidence |
Why no patient dosing range can be recommended from the available evidence
A patient dosing range needs human administration data, safety monitoring, and a clear clinical endpoint. The retrieved human studies do not provide that kind of published dosing basis for MOTS-c 1, 2, 4, 5.
Online dosing charts often mix animal data, anecdote, and clinic-style protocols. For a deeper discussion of why that is risky, see our guide to the MOTS-c peptide dosage protocol.
How to read online MOTS-c dosing claims carefully
- Ask whether the dose comes from a human study, an animal study, a cell study, or no cited study.
- Look for the actual endpoint: circulating MOTS-c is not the same as weight loss, insulin sensitivity, or symptom improvement.
- Be careful with claims that promise belly-fat loss, energy gains, anti-aging effects, or disease improvement without human outcome data.
- Avoid using “research use only” material in people; it is not made, labeled, or quality-controlled for patient use.
Legal status
| Date | Action | What it means | Source | Evidence |
|---|---|---|---|---|
| 2026-07-23 | Advisory committee reportedly voted 7-5-2 in favour of including MOTS-c on the 503A bulk drug substances list | Advisory vote only, as reported. FDA has not added it to the list, and the substance is not FDA-approved. | Healio (2026-07-24) | Reported — no agency record |
| 2026-07-23 | FDA convened the Pharmacy Compounding Advisory Committee to consider seven peptide bulk drug substances for the 503A list | The meeting establishes that these substances were formally considered. It does not change any substance's status. | FDA Advisory Committee Calendar | FDA / Federal Register |
This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-07. See the full legal-status tracker for every compound we follow.
Safety
MOTS-c safety is not settled because the retrieved human literature mostly measures circulating levels or biomarkers rather than testing MOTS-c as a patient treatment. The presence of human randomized studies does not remove the need for safety studies, adverse-event tracking, interaction data, and product-quality controls 1, 2, 4, 5.
What human studies can and cannot tell us about safety
The human randomized studies in the retrieved list help show that MOTS-c can be measured in settings such as exercise, metformin treatment, and heat stress. They do not establish a full adverse-effect profile for administered MOTS-c as a treatment 1, 2, 4, 5.
A review on approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance highlights that unapproved peptide use raises safety and efficacy questions. That is especially relevant when online sellers market peptides for performance or recovery without a clinician-led process 11.
Why preclinical findings do not prove human safety
Animal and cell findings can show a possible mechanism, but they do not prove human safety. For MOTS-c, animal metabolic findings and cell signaling findings are useful for research, yet they cannot answer whether a person should use the peptide or what risks might occur 9, 12.
Supply quality is a separate safety issue. Peptides sold for “research use only” may create risks around sterility, identity, concentration, impurities, storage, and handling. Our patient guide on finding a legitimate peptide source explains why licensed oversight matters.
Interactions
No dedicated MOTS-c drug-interaction studies have been published in the retrieved evidence. That is not reassurance; it means interaction risk is not well mapped in human use.
Diabetes, glucose-lowering drugs, and metabolic conditions
MOTS-c is being studied in metabolic settings, including a registered Phase 2 trial in adults with prediabetes and overweight or obesity. Because that question is active research rather than completed evidence, people using insulin, sulfonylureas, GLP-1 medications, SGLT2 inhibitors, or other glucose-lowering therapies should involve a licensed clinician before considering peptide use 13.
A human clinical study in type 2 diabetes and revascularized coronary artery disease examined mitochondrial-derived peptide-c along with β-amyloid, platelet reactivity, and adverse outcomes. This supports caution in people with complex cardiometabolic disease; it does not show that MOTS-c improves platelet reactivity or cardiovascular outcomes 3.
Cancer history, pregnancy, and complex medical conditions
Cancer-related MOTS-c research includes circulating MOTS-c in breast cancer patients treated with metformin and exercise-related MOTS-c changes in breast cancer survivors. These studies do not show that MOTS-c is a cancer therapy, so people with a cancer history should not treat those biomarker findings as a reason to self-use MOTS-c 1, 4.
A primary study reported MOTS-c-related findings in gestational diabetes mellitus and insulin resistance. Pregnancy is a setting where peptide decisions need extra caution and clinician oversight; preclinical or disease-marker findings should not be converted into self-treatment advice 6.
How to obtain it legally
The safe process for any peptide question starts with a licensed clinician who reviews your medical history, medications, goals, and risk factors. A prescription, when clinically appropriate, is different from buying a vial online from a “research chemical” seller.
Clinician evaluation before any peptide use
A clinician evaluation should cover why you are interested in MOTS-c, whether the goal is weight loss, insulin sensitivity, energy, exercise recovery, or longevity, and whether better-studied options fit the goal. It should also review pregnancy, cancer history, diabetes medications, cardiovascular disease, kidney disease, liver disease, and supplement use.
Licensed pharmacy process versus research-chemical vendors
A licensed pharmacy process includes a clinician’s prescription, pharmacy quality controls, labeling, storage instructions, and a way to ask follow-up questions. A research-chemical vendor is not a care team, and “not for human use” material is not the same as medication prepared for a patient.
Compounded medications, where discussed generally, are not FDA-approved. A prescription through Chia or any licensed telehealth clinic requires a medical evaluation and is never guaranteed.
Why Chia does not currently offer MOTS-c
Chia does not currently offer MOTS-c. We are saying that plainly because this page is meant to help you separate evidence from access claims. If your goal is to understand online access questions, our guide on whether you can buy MOTS-c peptide goes deeper.
What alternatives may be worth discussing with a licensed clinician?
If your interest in MOTS-c is really about weight, metabolic health, energy, or healthy aging, the next step is to name the goal first. Different goals point to different evidence levels, risks, and care paths.
Evidence-based weight-loss medications when weight loss is the goal
For weight loss, GLP-1 and GIP/GLP-1 medications have a different evidence base than MOTS-c. At Chia, we offer compounded semaglutide injection with microdosing plans available and compounded tirzepatide tablets or injection with microdosing plans available, when prescribed after an online evaluation by a licensed provider.
Those options are not substitutes for MOTS-c, and this page is not suggesting one treatment for every person. It is a practical distinction: if the goal is weight loss, a licensed clinician can compare better-studied weight-loss medications with investigational peptide claims.
Longevity-support protocols that do not rely on MOTS-c claims
If the goal is healthy aging or cellular-energy support, Chia offers certain longevity-focused treatments that are not MOTS-c, including NAD+, glutathione, sermorelin, and GHK-Cu cream, each only after clinician review where clinically appropriate. These should not be framed as proven lifespan-extending treatments.
You can also read our broader guide to mitochondrial peptides to compare MOTS-c with Humanin and other mitochondrial-derived peptides without turning early research into promises.
FAQ
MOTS-c is a mitochondrial-derived peptide, also called mitochondrial ORF of the 12S rRNA type-c. Researchers study it as a mitokine, meaning a signal linked to mitochondria, metabolism, exercise response, and cellular stress.
MOTS-c is studied for metabolic regulation, exercise physiology, insulin sensitivity, glucose metabolism, and biomarker changes in several disease settings. It should not be treated as a proven therapy for weight loss, diabetes, cancer, longevity, or athletic performance.
A complete side-effect profile for administered MOTS-c is not established from the retrieved human evidence. The main safety concerns are unknown adverse effects, possible interactions, and product-quality risks from unregulated or “research use only” sources.
Human evidence does not show that MOTS-c burns belly fat. Animal research has explored obesity and insulin resistance, but animal findings cannot be used as proof of human fat loss.
MOTS-c is being studied for insulin sensitivity and glucose metabolism, including in people with prediabetes and overweight or obesity. Registered trials are not the same as completed proof, so this remains an active research question.
No patient dosing recommendation can be made from the retrieved human evidence. The human studies listed here mainly measured circulating MOTS-c or biomarker changes rather than establishing a dosing range for patient treatment.
See the Legal status section on this page for the current status. As a safety rule, do not treat a research-chemical website as a medical source; peptide use should involve a licensed clinician and an appropriate pharmacy process.
No. Chia does not currently offer MOTS-c. We do offer certain clinician-reviewed weight-loss and longevity treatments, but MOTS-c is education-only on this page.
References
- 1.PMID 36490309 [randomised controlled trial] Cuyàs E, Verdura S, Martin-Castillo B, et al. Circulating levels of MOTS-c in patients with breast cancer treated with metformin. Aging. 2022.
- 2.PMID 34351816 [randomised controlled trial] von Walden F, Fernandez-Gonzalo R, Norrbom J, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. Journal of applied physiology (Bethesda, Md. : 1985). 2021.
- 3.PMID 32052315 [clinical trial] Ikonomidis I, Katogiannis K, Kyriakou E, et al. β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease. Journal of thrombosis and thrombolysis. 2020.
- 4.PMID 34413391 [randomised controlled trial] Dieli-Conwright CM, Sami N, Norris MK, et al. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Scientific reports. 2021.
- 5.PMID 40674654 [randomised controlled trial] Elhusseiny R, Ihsan M, Labidi M, et al. Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization. Medicine and science in sports and exercise. 2025.
- 6.PMID 34798268 [primary study] Yin Y, Pan Y, He J, et al. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. Pharmacological research. 2022.
- 7.PMID 35656563 [review/secondary] Yoon TK, Lee CH, Kwon O, et al. Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c). Diabetes & metabolism journal. 2022.
- 8.PMID 36761202 [review/secondary] Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in endocrinology. 2023.
- 9.PMID 25738459 [primary study] Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell metabolism. 2015.
- 10.PMID 39321430 [primary study] Yin Y, Li Y, Ma B, et al. Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024.
- 11.PMID 41966639 [review/secondary] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.). 2026.
- 12.PMID 29983246 [primary study] Kim KH, Son JM, Benayoun BA, et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell metabolism. 2018.
- 13.NCT07505745 [RECRUITING, PHASE2, n=120] MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity. ClinicalTrials.gov. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
